WO2006121742A2 - Formulations of a src/abl inhibitor - Google Patents
Formulations of a src/abl inhibitor Download PDFInfo
- Publication number
- WO2006121742A2 WO2006121742A2 PCT/US2006/017073 US2006017073W WO2006121742A2 WO 2006121742 A2 WO2006121742 A2 WO 2006121742A2 US 2006017073 W US2006017073 W US 2006017073W WO 2006121742 A2 WO2006121742 A2 WO 2006121742A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- microcrystalline cellulose
- pharmaceutical composition
- Prior art date
Links
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Cc(cccc1Cl)c1NC(c1cnc(Nc2nc(C)nc(N3CCN(CCO)CC3)c2)[s]1)=O Chemical compound Cc(cccc1Cl)c1NC(c1cnc(Nc2nc(C)nc(N3CCN(CCO)CC3)c2)[s]1)=O ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the compound of formula (I) 'N- (2-Chloro-6- methylphenyl ) -2- [ [6- [4- (2-hydroxyethyl) -1-piperazinyl] -2- methyl-4 -pyrimidinyl] amino] -5-thiazolecarboxamide, is a protein tyrosine kinase inhibitor, including Src Kinase, Bcr/Abl inhibitor, and is also known as a Src/Abl inhibitor and is useful in the treatment of oncological and immunologic diseases.
- the compound of formula (I) and its preparation have been previously described in U.S. Patent No. 6,596,746, issued July 22, 2003.
- the use of the compound in the treatment of oncological and immunological disorders is described therein and in US Patent Publication No. US20040054186, published March 18, 2004, which are both herein incorporated by reference.
- the compound is, in one embodiment, a crystalline monohydrate form such as described in U.S. Patent Application Serial No.
- the compound of formula (I) may exist in other crystalline forms, either as a neat compound or as a solvate.
- compositions of the compound of formula (I) and to methods of treating immunologic and oncological disorders. Additionally, disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of formula (I) , solvate, hydrate, pharmaceutically acceptable salt or prodrug form thereof.
- One embodiment is directed to pharmaceutical compositions having a non-reactive coating.
- Another aspect is directed to pharmaceutical compositions having a non-reactive coating, wherein the non-reactive coating does not cause decomposition of the compound of formula (I) .
- the pharmaceutical composition having a non-reactive coating does not cause decomposition of the compound of formula (I) at varying concentrations of the compound of formula (I) and/or at high temperature and/or humidity.
- Another aspect is directed to pharmaceutical compositions having improved compactability properties.
- the present disclosure is directed to pharmaceutical compositions having both intragranular and extragranular microcrystalline cellulose.
- Another embodiment provides the use of pharmaceutical compositions for the manufacture of a medicament for the treatment of oncological and immunological diseases.
- One embodiment is directed to a pharmaceutical composition for oral administration comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I) or solvate, hydrate, or pharmaceutically acceptable salt thereof,
- Another embodiment is directed to a pharmaceutical composition of the compound of formula (I) wherein the non-reactive coating does not react with the compound of formula (I) .
- Another embodiment is directed to a pharmaceutical composition of the compound of formula (I) wherein the non-reactive coating is a coating having polyethylene glycol as plasticizer.
- Another embodiment is directed to a pharmaceutical composition of the compound of formula (I) wherein the pharmaceutically acceptable carrier comprises lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, and magnesium stearate.
- the pharmaceutically acceptable carrier comprises lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, and magnesium stearate.
- Another embodiment is directed to a pharmaceutical composition of the compound of formula (I) wherein the microcrystalline cellulose is present in both intragranular and extragranular phase.
- Another embodiment is directed to a pharmaceutical composition of the compound of formula (I) wherein 15% by weight of the microcrystalline cellulose is extragranular .
- Another embodiment is directed to a pharmaceutical composition for oral administration comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I)
- composition (D solvate, hydrate, or pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable carrier comprises intragranular and extragranular microcrystalline cellulose .
- pharmaceutically acceptable carrier comprises intragranular and extragranular microcrystalline cellulose .
- Another embodiment is directed to a pharmaceutical composition of the compound of formula (I) wherein the extragranular microcrystalline cellulose is about 15% by weight .
- Another embodiment is directed to a pharmaceutical composition of the compound of formula (I) wherein the composition further comprises a non-reactive coating.
- Another embodiment is directed to a pharmaceutical composition of the compound of formula (I) wherein the non-reactive coating is a coating having polyethylene glycol as plasticizer.
- a main component of the composition is the compound of formula (I) , a Src/Abl inhibitor present in a therapeutically effective amount along with a pharmaceutically acceptable carrier.
- Another embodiment is directed to a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I)
- Another embodiment is directed to a pharmaceutical composition wherein the particle size of the compound of formula (I) less than or equal to about 130 microns.
- the invention may be embodied in other forms without departing from the spirit or essential attributes thereof. This invention also encompasses all combinations of alternative aspects and embodiments of the invention noted herein. It is understood that any and all embodiments of the present invention may be taken in conjunction with any other embodiment to describe additional embodiments of the present invention. Furthermore, any elements of an embodiment are meant to be combined with any and all other elements from any of the embodiments to describe additional embodiments.
- the compound of formula (I) is a crystalline monohydrate and the range for the compound of formula (I) in the composition can vary from about 5 to 50% by weight . In another embodiment, the drug substance component will range from about 20 to 30% by weight in the composition.
- lactose monohydrate wherein the component can vary from about 0- 45% by weight. Alternatively, the component is about 29- 38% by weight. Alternatively, lactose monohydrate may be replaced with dicalcium carbonate or mannitol .
- Another component is microcrystalline cellulose or silicified microcrystalline cellulose which can vary from about 20 to about90% by weight. Alternatively, it may be present in the range of about 29-38% by weight.
- Another component is hydroxypropyl cellulose which can vary from about 1-5% by weight or pregelatinized starch which can vary from about 5-10% by weight. Alternatively, it may be present at about 3% or 5% by weight.
- Another component is croscarmellose sodium or sodium starch glycolate which can vary from about 2 to 8% by weight. Alternatively, it may be present at about 4% by weight.
- Another component is magnesium stearate which can vary from about 0.25 - 1% by weight or sodium stearyl fumarate which can vary from 0.5-2% by weight. Alternatively, it may be present at about 0.5% by weight for magnesium stearate or at about 1% by weight for sodium stearyl fumarate.
- Another component is sodium lauryl sulfate which can vary from 0-2% by weight. Alternately, it may be present at about 1% by weight.
- the composition is formed into tablets and is then coated with a non-reactive coating.
- the non-reactive coating is one which does not cause degradation of the compound of formula (I) within the tablet.
- compositions have plasticizers present which may react with the compound of formula (I) producing unwanted impurities in the compositions.
- An embodiment of the compositions utilizes coatings having non-reactive plasticizers .
- Such coatings which may be useful are those have plasticizers such as polyhydric alcohols, phthalate esters, glycerides and oils.
- plasticizers such as polyhydric alcohols, phthalate esters, glycerides and oils.
- polyhydric alcohols include, but are not limited to, propylene glycol glycerol, and polyethylene glycols.
- phthalate esters include, but are not limited to, diethylphthalate .
- An example of a glycerides includes, but is not limited to, acetylated monoglycerides .
- oils examples include, but are not limited to, castor oil and mineral oil.
- the plasticizer contains the plasticizer polyethylene glycol.
- Such coating is distributed under the name Opadry ®
- White sold by Colorcon, containing hydroxypropylmethylcellulose, titanium dioxide, and polyethylene glycol .
- a formulation using larger particle size of the compound (I) was found to have poor compression properties when all of microcrystalline cellulose is added intragranularly. Conversely, the formulation using particle size of the compound (I) with D90 up to about 130 ⁇ m was found to have acceptable compression properties when portion of the microcrystalline cellulose is added in the extragranular phase. Alternatively, the particle size of the compound (I) (D90 ⁇ 120 ⁇ m) was found to have poor compression properties when all of microcrystalline cellulose is added intragranularly. Conversely, the formulation using particle size of the compound (I) with D90 up to about 130 ⁇ m was found to have acceptable compression properties when portion of the microcrystalline cellulose is added in the extragranular phase. Alternatively, the particle size of the compound
- (I) may be up to or equal to 150 ⁇ m.
- improved compactibility properties includes, but is not limited to, tablets with desired mechanical strength which can be manufactured reproducibly at reasonable compression speeds and forces.
- Nonreactive coating includes, but is not limited to, coating ingredients which do not react with the compound of interest to form degradant(s) at any storage conditions.
- introductiongranular includes, but is not limited to, the components added or the process steps prior to the drying of the granulation (for example, prior to step 3 of the process as described below) .
- extractive includes, but is not limited to, the components added or the process steps after the drying of the water (for example, after step 3 of the process as described below) .
- All numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth that are preceded by the word “about” are to be understood as only approximations so that slight variations above and below the stated number may be used to achieve substantially the same results as the stated number. Accordingly, unless indicated to the contrary, numerical parameters preceded by the word “about” are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques .
- each of the variously stated ranges is intended to be continuous so as to include each numerical parameter between the stated minimum and maximum value of each range. It is to be further understood that, while not intending to limit the applicability of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in a manner consistent with the reported number of significant digits for each numerical parameter and by applying ordinary rounding techniques.
- a number may be contained within a numerical range wherein at least one of the minimum and maximum numbers of the range is or is not preceded by the word "about” , each numerical value contained within the range may or may not be preceded by the word "about”.
- a range of about 1 to about 10 includes about 1, about 2, 2, about 3, 3, about 4 , 4 , about 5 , 5 , about 6 , 6 , about 7 , 7 , about 8 , 8 , about 9, 9, and about 10.
- step [3] Pass the dried granulation from step [3] through an appropriate screen or mill.
- compositions of the present invention are useful for the treatment of cancers such as chronic myelogenous leukemia (CML) , gastrointestinal stromal tumor (GIST) , small cell lung cancer (SCLC) , non- small cell lung cancer (NSCLC) , ovarian cancer, melanoma, mastocytosis, germ cell tumors, acute myelogenous leukemia (AML) , pediatric sarcomas, breast cancer, colorectal cancer, pancreatic cancer, prostate cancer, Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) and others known to be associated with protein tyrosine kinases such as, for example, SRC, BCR- ABL and c-KIT.
- cancers such as chronic myelogenous leukemia (CML) , gastrointestinal stromal tumor (GIST) , small cell lung cancer (SCLC) , non- small cell lung cancer (NSCLC) , ovarian cancer, melanoma, mast
- compositions of the present invention are also useful in the treatment of cancers that are sensitive to and resistant to chemotherapeutic agents that target BCR-ABL and c-KIT, such as, for example, Gleevec ® (STI-571) , and is useful in the treatment of patients resistant or intolerant to Gleevec ® (STI-571) or AMN-107 for diseases such as chronic myelogenous leukemias (CML) , or other cancers (including other leukemias) as described herein.
- chemotherapeutic agents that target BCR-ABL and c-KIT
- STI-571 Gleevec ®
- AMN-107 for diseases such as chronic myelogenous leukemias (CML) , or other cancers (including other leukemias) as described herein.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK06769997.5T DK1885339T3 (en) | 2005-05-05 | 2006-05-04 | FORMULATIONS OF A SRC / ABL INHIBITOR |
JP2008510188A JP5173794B2 (en) | 2005-05-05 | 2006-05-04 | SRC / ABL inhibitor |
PL06769997T PL1885339T3 (en) | 2005-05-05 | 2006-05-04 | Formulations of a src/abl inhibitor |
SI200631971T SI1885339T1 (en) | 2005-05-05 | 2006-05-04 | Formulations of a src/abl inhibitor |
EP06769997.5A EP1885339B1 (en) | 2005-05-05 | 2006-05-04 | Formulations of a src/abl inhibitor |
RS20150635A RS54258B1 (en) | 2005-05-05 | 2006-05-04 | Formulations of a src/abl inhibitor |
ES06769997.5T ES2546847T3 (en) | 2005-05-05 | 2006-05-04 | Formulations of a Src / Abl inhibitor |
NO20075154A NO343939B1 (en) | 2005-05-05 | 2007-10-10 | Formulations of an src / abl inhibitor |
HRP20151051TT HRP20151051T1 (en) | 2005-05-05 | 2015-10-05 | Formulations of a src/abl inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67803005P | 2005-05-05 | 2005-05-05 | |
US60/678,030 | 2005-05-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006121742A2 true WO2006121742A2 (en) | 2006-11-16 |
WO2006121742A3 WO2006121742A3 (en) | 2007-02-22 |
Family
ID=37076246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/017073 WO2006121742A2 (en) | 2005-05-05 | 2006-05-04 | Formulations of a src/abl inhibitor |
Country Status (18)
Country | Link |
---|---|
US (2) | US20060251723A1 (en) |
EP (1) | EP1885339B1 (en) |
JP (1) | JP5173794B2 (en) |
CN (2) | CN102813655A (en) |
AR (1) | AR054445A1 (en) |
DK (1) | DK1885339T3 (en) |
ES (1) | ES2546847T3 (en) |
GE (1) | GEP20104927B (en) |
HR (1) | HRP20151051T1 (en) |
HU (1) | HUE026040T2 (en) |
NO (1) | NO343939B1 (en) |
PE (1) | PE20061373A1 (en) |
PL (1) | PL1885339T3 (en) |
PT (1) | PT1885339E (en) |
RS (1) | RS54258B1 (en) |
SI (1) | SI1885339T1 (en) |
TW (1) | TWI386205B (en) |
WO (1) | WO2006121742A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011095588A1 (en) | 2010-02-04 | 2011-08-11 | Ratiopharm Gmbh | Pharmaceutical composition comprising n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid |
WO2015107545A1 (en) | 2013-12-18 | 2015-07-23 | Dharmesh Mahendrabhai Shah | Water soluble salts of dasatinib hydrate |
WO2017144109A1 (en) | 2016-02-25 | 2017-08-31 | Remedica Ltd | Dasatinib formulation |
EP4071248A1 (en) | 2021-04-07 | 2022-10-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Means and methods for enhancing receptor-targeted gene transfer |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2260592C9 (en) | 1999-04-15 | 2017-04-07 | Бристол-Маерс Сквибб Ко. | Cyclic inhibitors of protein-tyrosine kinases |
JP5173794B2 (en) | 2005-05-05 | 2013-04-03 | ブリストル−マイヤーズ スクイブ カンパニー | SRC / ABL inhibitor |
US8247419B2 (en) * | 2005-06-09 | 2012-08-21 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant kit protein |
US20070105867A1 (en) * | 2005-09-21 | 2007-05-10 | Bristol-Myers Squibb Company | Oral administration of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
WO2007109527A1 (en) * | 2006-03-17 | 2007-09-27 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides |
US20090318560A1 (en) * | 2007-02-26 | 2009-12-24 | Wayne Parent | Formulations for cathepsin k inhibitors |
CN101891738B (en) | 2010-02-08 | 2011-09-28 | 南京卡文迪许生物工程技术有限公司 | Dasatinib polymorph and preparation method and medical composition thereof |
JP5589097B2 (en) * | 2010-02-08 | 2014-09-10 | 南京▲か▼文迪許生物工程技術有限公司 | Dasatinib polycrystal, preparation method thereof and drug composition |
CN104274420B (en) * | 2013-07-11 | 2019-03-05 | 石药集团中奇制药技术(石家庄)有限公司 | A kind of Dasatinib composition and preparation method thereof |
JP7166754B2 (en) * | 2017-11-22 | 2022-11-08 | 沢井製薬株式会社 | Formulations containing dasatinib anhydrate |
JP7249397B2 (en) * | 2017-12-27 | 2023-03-30 | 日本化薬株式会社 | Pharmaceutical composition containing dasatinib as an active ingredient |
JP7000148B2 (en) * | 2017-12-27 | 2022-01-19 | 日本化薬株式会社 | A pharmaceutical composition containing dasatinib as an active ingredient |
WO2020018053A2 (en) * | 2018-05-25 | 2020-01-23 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | The tablet comprising dasatinib |
TWI787523B (en) | 2018-06-15 | 2022-12-21 | 漢達生技醫藥股份有限公司 | Crystalline of dasatinib lauryl sulfate salt |
GB2592680A (en) | 2020-03-06 | 2021-09-08 | Zentiva Ks | Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596746B1 (en) | 1999-04-15 | 2003-07-22 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US20040054186A1 (en) | 1999-04-15 | 2004-03-18 | Jagabandhu Das | Cyclic protein tyrosine kinase inhibitors |
US20050215795A1 (en) | 2004-02-06 | 2005-09-29 | Bang-Chi Chen | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3539380A (en) | 1968-01-08 | 1970-11-10 | Upjohn Co | Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms |
US4543370A (en) | 1979-11-29 | 1985-09-24 | Colorcon, Inc. | Dry edible film coating composition, method and coating form |
US5681382A (en) | 1995-08-22 | 1997-10-28 | Shin-Etsu Chemical Co., Ltd. | Rapidly soluble coating composition and method for preparing same |
AR016827A1 (en) * | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL TABLET |
PL351069A1 (en) * | 1999-12-08 | 2003-03-10 | Pharmacia Corp | Valdecoxib compositions |
GB0209257D0 (en) * | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
US7491725B2 (en) * | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
TWI338004B (en) * | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
JP5173794B2 (en) | 2005-05-05 | 2013-04-03 | ブリストル−マイヤーズ スクイブ カンパニー | SRC / ABL inhibitor |
-
2006
- 2006-05-04 JP JP2008510188A patent/JP5173794B2/en active Active
- 2006-05-04 GE GEAP200610410A patent/GEP20104927B/en unknown
- 2006-05-04 ES ES06769997.5T patent/ES2546847T3/en active Active
- 2006-05-04 AR ARP060101816A patent/AR054445A1/en not_active Application Discontinuation
- 2006-05-04 WO PCT/US2006/017073 patent/WO2006121742A2/en active Application Filing
- 2006-05-04 EP EP06769997.5A patent/EP1885339B1/en not_active Revoked
- 2006-05-04 CN CN2012103135834A patent/CN102813655A/en active Pending
- 2006-05-04 PT PT67699975T patent/PT1885339E/en unknown
- 2006-05-04 RS RS20150635A patent/RS54258B1/en unknown
- 2006-05-04 SI SI200631971T patent/SI1885339T1/en unknown
- 2006-05-04 US US11/418,338 patent/US20060251723A1/en not_active Abandoned
- 2006-05-04 HU HUE06769997A patent/HUE026040T2/en unknown
- 2006-05-04 CN CNA2006800150680A patent/CN101170996A/en active Pending
- 2006-05-04 PL PL06769997T patent/PL1885339T3/en unknown
- 2006-05-04 DK DK06769997.5T patent/DK1885339T3/en active
- 2006-05-05 TW TW095116078A patent/TWI386205B/en active
- 2006-05-05 PE PE2006000477A patent/PE20061373A1/en not_active Application Discontinuation
-
2007
- 2007-10-10 NO NO20075154A patent/NO343939B1/en unknown
-
2013
- 2013-01-07 US US13/735,081 patent/US20130122093A1/en not_active Abandoned
-
2015
- 2015-10-05 HR HRP20151051TT patent/HRP20151051T1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596746B1 (en) | 1999-04-15 | 2003-07-22 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US20040054186A1 (en) | 1999-04-15 | 2004-03-18 | Jagabandhu Das | Cyclic protein tyrosine kinase inhibitors |
US20050215795A1 (en) | 2004-02-06 | 2005-09-29 | Bang-Chi Chen | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Non-Patent Citations (1)
Title |
---|
See also references of EP1885339A2 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011095588A1 (en) | 2010-02-04 | 2011-08-11 | Ratiopharm Gmbh | Pharmaceutical composition comprising n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid |
EP2359813A1 (en) | 2010-02-04 | 2011-08-24 | Ratiopharm GmbH | Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid |
WO2015107545A1 (en) | 2013-12-18 | 2015-07-23 | Dharmesh Mahendrabhai Shah | Water soluble salts of dasatinib hydrate |
WO2017144109A1 (en) | 2016-02-25 | 2017-08-31 | Remedica Ltd | Dasatinib formulation |
EP4071248A1 (en) | 2021-04-07 | 2022-10-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Means and methods for enhancing receptor-targeted gene transfer |
WO2022214588A1 (en) | 2021-04-07 | 2022-10-13 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Means and methods for enhancing receptor-targeted gene transfer |
Also Published As
Publication number | Publication date |
---|---|
CN102813655A (en) | 2012-12-12 |
JP5173794B2 (en) | 2013-04-03 |
EP1885339B1 (en) | 2015-07-29 |
WO2006121742A3 (en) | 2007-02-22 |
PT1885339E (en) | 2015-10-12 |
RS54258B1 (en) | 2016-02-29 |
CN101170996A (en) | 2008-04-30 |
US20060251723A1 (en) | 2006-11-09 |
PL1885339T3 (en) | 2015-12-31 |
US20130122093A1 (en) | 2013-05-16 |
EP1885339A2 (en) | 2008-02-13 |
GEP20104927B (en) | 2010-03-25 |
NO20075154L (en) | 2008-02-01 |
HRP20151051T1 (en) | 2015-11-06 |
TWI386205B (en) | 2013-02-21 |
SI1885339T1 (en) | 2015-10-30 |
AR054445A1 (en) | 2007-06-27 |
JP2008540440A (en) | 2008-11-20 |
HUE026040T2 (en) | 2016-05-30 |
ES2546847T3 (en) | 2015-09-29 |
DK1885339T3 (en) | 2015-10-19 |
PE20061373A1 (en) | 2006-12-15 |
NO343939B1 (en) | 2019-07-15 |
TW200716117A (en) | 2007-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1885339B1 (en) | Formulations of a src/abl inhibitor | |
KR20180109992A (en) | A pharmaceutical composition comprising a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof | |
WO2006040779A2 (en) | Controlled release gastric floating matrix formulation containing imatinib | |
CA2651138C (en) | Pharmaceutical composition | |
WO2017033107A1 (en) | Pharmaceutical compositions comprising afatinib | |
WO2018185175A1 (en) | Pharmaceutical composition comprising lenvatinib mesylate | |
JP7094944B2 (en) | Pharmaceutical composition containing rosuvastatin and ezetimibe and method for preparing the same | |
TW201821063A (en) | Pharmaceutical composition comprising two different active ingredients | |
EP3378479B1 (en) | Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof | |
JP6864691B2 (en) | A pharmaceutical composition containing a quinoline derivative or a salt thereof. | |
WO2010010367A1 (en) | Solid pharmaceutical composition comprising exemestane | |
EP3154525B1 (en) | Pharmaceutical composition comprising a triazole antifungal agent and method for preparation thereof | |
KR102203229B1 (en) | Pharmaceutical composition with improved dissolution rate comprising nebivolol | |
JP2021518422A (en) | Pharmaceutical composition containing lenalidomide | |
JP7370124B2 (en) | Pharmaceutical tablets containing erlotinib as the active ingredient | |
JP5563371B2 (en) | Oral tablets containing quetiapine fumarate | |
EP2803353A1 (en) | Compositions of Imatinib | |
JP2021070658A (en) | Abiraterone acetate-containing preparation | |
JP2022042886A (en) | Pharmaceutical preparation comprising abiraterone acetate | |
JP2019059685A (en) | Pharmaceutical tablets containing erlotinib as active ingredient | |
JP2021070659A (en) | Abiraterone acetate-containing preparation | |
JP2024007795A (en) | Ezetimibe/rosuvastatin-compounded tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680015068.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006769997 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007502229 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 07116475 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2008510188 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10410 Country of ref document: GE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200702594 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2015/0635 Country of ref document: RS |